All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The PsOPsA Hub is supported by educational grants. All educational content is developed independently by SES in collaboration with our expert steering committee, with no input or influence from financial supporters. We would like to express our gratitude to the following companies for their support: • UCB: For website development, launch, and ongoing maintenance. • UCB: For educational content and news updates.
CRYSTAL-Greece: Disease severity and QoL with systemic treatments in psoriasis
By Ella Dixon
|
Systemic therapies are commonly used in patients with moderate-to-severe psoriasis, or in those who have not responded to topical treatment. However, there are limited real-world data on rates of complete skin clearance and disease burden in patients with psoriasis. CRYSTAL-Greece was a multicenter, single-country retrospective chart study which analyzed data from 280 Greek patients with moderate-to-severe plaque psoriasis. Enrolled patients had been on continuous treatment with a systemic therapy for ≥24 weeks. Their PASI score was evaluated at the study visit and used to confirm current disease severity. Results from the study were published by Rigopoulos et al. in the Journal of Dermatological Treatment. At diagnosis, the median patient age was 29.9 years, and baseline physician-reported psoriasis severity was mild in 38.5%, moderate in 35.2%, and severe in 26.3% of cases. |
| Key learnings |
| The median absolute PASI score was reduced from 14.7 to 1.8 from time of current systemic therapy initiation to study visit. PASI scores of ≤1, ≤3, and ≤5 were achieved by 36.8%, 64.6%, and 83.9% of patients, respectively, indicating persistent disease. |
| At the study visit, 18.9% of patients had a DLQI score >5 with 58.6% of patients reporting anxiety/depression and 28.6% experiencing pain/discomfort after treatment with systemic therapy for ≥24 weeks. |
| Absolute PASI >5 rates were 13.7% in the biologic and 28.9% in the nonbiologic monotherapy subgroups, respectively. More patients receiving biologic treatments were completely satisfied with the treatment (49.3%) compared with patients receiving nonbiologics (17.8% ). |
| Complete skin clearance remains an unmet need in many patients with psoriasis. Biologic therapies, including those targeting TNF, IL-17, and IL-12/23 pathways show promise for improving outcomes in moderate-to-severe disease. |
Abbreviations: DLQI, Dermatology Life Quality Index; IL, interleukin; PASI, Psoriasis Area and Severity Index; TNF, tumor necrosis factor.
- Rigopoulos D, Katsantonis J, Neofotistou O, et al. Psoriasis severity in moderate to severe psoriatic Greek patients routinely treated with systemic treatment: a cross-sectional and retrospective chart review study (CRYSTAL-Greece). J Dermatolog Treat. 2025;36(1):2402344. DOI: 1080/09546634.2024.2402344
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox